2024
Intravascular Imaging–Guided Versus Angiography‐Guided Percutaneous Coronary Intervention: A Systematic Review and Meta‐Analysis of Randomized Trials
Sreenivasan J, Reddy R, Jamil Y, Malik A, Chamie D, Howard J, Nanna M, Mintz G, Maehara A, Ali Z, Moses J, Chen S, Chieffo A, Colombo A, Leon M, Lansky A, Ahmad Y. Intravascular Imaging–Guided Versus Angiography‐Guided Percutaneous Coronary Intervention: A Systematic Review and Meta‐Analysis of Randomized Trials. Journal Of The American Heart Association 2024, 13: e031111. PMID: 38214263, PMCID: PMC10926835, DOI: 10.1161/jaha.123.031111.Peer-Reviewed Original ResearchConceptsAdverse cardiac eventsPercutaneous coronary interventionAngiography-guided percutaneous coronary interventionTarget vessel revascularizationTarget-lesion revascularizationCardiac eventsCardiac deathImaging-guided percutaneous coronary interventionWeighted mean follow-up durationMeta-analysisPrimary outcomeMean follow-up durationStent thrombosisMeta-analysis of randomized trialsStudy-level meta-analysisComplex lesion subsetsIntravascular imagingAll-cause deathRandom-effects meta-analysisStandard of careIntention-to-treat principleUpdates of clinical guidelinesMixed-effects meta-regressionComplex percutaneous coronary interventionIntravascular imaging-guided percutaneous coronary intervention
2022
Percutaneous Coronary Intervention vs. Coronary Artery Bypass Grafting for Treating In-Stent Restenosis in Unprotected-Left Main: LM-DRAGON-Registry
Wańha W, Bil J, Kołodziejczak M, Kowalówka A, Kowalewski M, Hudziak D, Gocoł R, Januszek R, Figatowski T, Milewski M, Tomasiewicz B, Kübler P, Hrymniak B, Desperak P, Kuźma Ł, Milewski K, Góra B, Łoś A, Kulczycki J, Włodarczak A, Skorupski W, Grygier M, Lesiak M, D'Ascenzo F, Andres M, Kleczynski P, Litwinowicz R, Borin A, Smolka G, Reczuch K, Gruchała M, Gil RJ, Jaguszewski M, Bartuś K, Suwalski P, Dobrzycki S, Dudek D, Bartuś S, Ga̧sior M, Ochała A, Lansky AJ, Deja M, Legutko J, Kedhi E, Wojakowski W. Percutaneous Coronary Intervention vs. Coronary Artery Bypass Grafting for Treating In-Stent Restenosis in Unprotected-Left Main: LM-DRAGON-Registry. Frontiers In Cardiovascular Medicine 2022, 9: 849971. PMID: 35615559, PMCID: PMC9125786, DOI: 10.3389/fcvm.2022.849971.Peer-Reviewed Original ResearchPercutaneous coronary interventionTarget vessel revascularizationCoronary artery bypassCardiac deathMyocardial infarctionPCI groupArtery bypassCoronary interventionStent restenosisUnprotected left main coronary arteryLeft main coronary arteryMain coronary arteryManagement of patientsAnalysis of patientsCerebrovascular eventsPrimary endpointVessel revascularizationConsecutive patientsCoronary arteryCABGLower incidenceLower riskPatientsDeathMACCE
2021
Long term outcomes of ultrathin versus standard thickness second‐generation drug eluting stents: Meta‐analysis of randomized trials
Hussain Y, Gaston S, Kluger J, Shah T, Yang Y, Tirziu D, Lansky A. Long term outcomes of ultrathin versus standard thickness second‐generation drug eluting stents: Meta‐analysis of randomized trials. Catheterization And Cardiovascular Interventions 2021, 99: 563-574. PMID: 34236755, DOI: 10.1002/ccd.29866.Peer-Reviewed Original ResearchConceptsSecond generation drug eluting stentsTarget lesion failureDrug eluting stentsLong-term outcomesEluting stentsTerm outcomesRisk ratioIschemia-driven target vessel revascularizationTarget vessel myocardial infarctionLong-term clinical outcomesProbable stent thrombosisTarget vessel revascularizationTerm clinical outcomesVessel myocardial infarctionPercutaneous coronary interventionCoronary artery diseaseConfidence intervalsFirst generation drug eluting stentsRandom-effects modelLesion failureVessel revascularizationCoronary interventionSecondary outcomesArtery diseaseCardiac death
2020
Long‐term serial functional evaluation after implantation of the Fantom sirolimus‐eluting bioresorbable coronary scaffold
Saito Y, Cristea E, Bouras G, Abizaid A, Lutz M, Carrié D, Weber‐Albers J, Dudek D, Anderson J, Lansky A, Investigators T. Long‐term serial functional evaluation after implantation of the Fantom sirolimus‐eluting bioresorbable coronary scaffold. Catheterization And Cardiovascular Interventions 2020, 97: 431-436. PMID: 32077590, DOI: 10.1002/ccd.28804.Peer-Reviewed Original ResearchConceptsPost-percutaneous coronary interventionQuantitative flow ratioBioresorbable coronary scaffoldTarget vessel revascularizationVessel revascularizationFunctional ischemiaStable coronary artery diseaseTime of revascularizationCoronary artery diseaseFractional flow reserveQFR assessmentII trialAngiographic outcomesCoronary interventionUnstable anginaArtery diseaseQFR valueWire-based fractional flow reserveSignificant lesionsFlow reservePatientsTarget vesselRevascularizationQFR analysisFunctional evaluation
2017
Nine‐month results of the BIOHELIX‐I clinical trial study: Evaluation of the PRO‐Kinetic Energy cobalt chromium bare‐metal stent system
Michael TT, Richardt G, Lansky A, Carney RJ, Khan MA, Shehadeh A, Zeymer U, Gupta S. Nine‐month results of the BIOHELIX‐I clinical trial study: Evaluation of the PRO‐Kinetic Energy cobalt chromium bare‐metal stent system. Catheterization And Cardiovascular Interventions 2017, 92: 1030-1039. PMID: 29271575, DOI: 10.1002/ccd.27434.Peer-Reviewed Original ResearchConceptsTarget vessel revascularizationCoronary artery diseaseIschemia-driven target vessel revascularizationBare metal stentsTarget vessel failureTVF ratePrimary endpointStent systemSymptomatic coronary artery diseaseTarget lesion revascularization rateSingle-arm clinical trialNine‐month resultsDual antiplatelet therapyLesion revascularization rateMean patient agePercutaneous coronary interventionSubset of patientsClinical trial studyPrespecified performance goalArm clinical trialCoronary stent systemDrug-eluting stentsMean lesion lengthMajority of implantsEligible patients
2015
Pretreatment with aspirin in acute coronary syndromes: Lessons from the ACUITY and HORIZONS-AMI trials
Brener SJ, Mehran R, Lansky AJ, Ayele GM, Stone GW. Pretreatment with aspirin in acute coronary syndromes: Lessons from the ACUITY and HORIZONS-AMI trials. European Heart Journal Acute Cardiovascular Care 2015, 5: 449-454. PMID: 26722003, DOI: 10.1177/2048872615624848.Peer-Reviewed Original ResearchConceptsAcute coronary syndromeHORIZONS-AMI trialCoronary syndromeAspirin pretreatmentMyocardial infarctionCardiac deathStent thrombosisSegment elevation acute coronary syndromesST-segment elevation myocardial infarctionElevation acute coronary syndromeAcute coronary syndrome patientsLarge randomized clinical trialsAdverse ischemic eventsTarget vessel revascularizationCoronary syndrome patientsIndependent risk factorElevation myocardial infarctionLarge prospective studiesHigh-risk cohortIncidence of deathRandomized clinical trialsMultivariable regression analysisPrior revascularizationVessel revascularizationIschemic events
2013
Impact of advanced age on the safety and effectiveness of paclitaxel‐eluting stent implantation in patients with ST‐segment elevation myocardial infarction undergoing primary angioplasty
Dudek D, Mehran R, Dziewierz A, Witzenbichler B, Brodie BR, Kornowski R, Fahy M, Lansky AJ, Rakowski T, Legutko J, Bryniarski L, Stone GW. Impact of advanced age on the safety and effectiveness of paclitaxel‐eluting stent implantation in patients with ST‐segment elevation myocardial infarction undergoing primary angioplasty. Catheterization And Cardiovascular Interventions 2013, 82: 869-877. PMID: 23359554, DOI: 10.1002/ccd.24813.Peer-Reviewed Original ResearchConceptsPrimary percutaneous coronary interventionST-segment elevation myocardial infarctionPaclitaxel-eluting stent implantationPrimary PCIBare metal stentsElevation myocardial infarctionYears of ageStent implantationOlder patientsMyocardial infarctionLower riskIschemic target vessel revascularizationMajor adverse cardiac eventsHORIZONS-AMI studyHORIZONS-AMI trialReduction of MACEAdverse cardiac eventsTarget vessel revascularizationClinical end pointsPercutaneous coronary interventionLong-term resultsImpact of ageCause deathMajor bleedingPrimary angioplastyRelationship Between ST-Segment Recovery and Clinical Outcomes After Primary Percutaneous Coronary Intervention
Farkouh ME, Reiffel J, Dressler O, Nikolsky E, Parise H, Cristea E, Baran DA, Dizon J, Merab JP, Lansky AJ, Mehran R, Stone GW. Relationship Between ST-Segment Recovery and Clinical Outcomes After Primary Percutaneous Coronary Intervention. Circulation Cardiovascular Interventions 2013, 6: 216-223. PMID: 23652600, DOI: 10.1161/circinterventions.112.000142.Peer-Reviewed Original ResearchMeSH KeywordsAgedChi-Square DistributionCoronary AngiographyElectrocardiographyFemaleFibrinolytic AgentsHumansKaplan-Meier EstimateMaleMiddle AgedMultivariate AnalysisMyocardial InfarctionPercutaneous Coronary InterventionPlatelet Aggregation InhibitorsProportional Hazards ModelsRecovery of FunctionRisk FactorsStentsTime FactorsTreatment OutcomeConceptsPrimary percutaneous coronary interventionST-segment elevation myocardial infarctionPrimary PCIMajor adverse cardiovascular eventsST-segment resolutionAdverse cardiovascular eventsIschemia-driven target vessel revascularizationComplete ST-segment resolutionTarget vessel revascularizationPercutaneous coronary interventionMyocardial infarctionCardiovascular eventsVessel revascularizationCoronary interventionIndependent predictorsDegree of STRBaseline ST-segment elevationAcute Myocardial Infarction trialLong-term prognostic valueLong-term cardiovascular mortalityLeft ventricular ejection fractionLong-term predictive valuePost-PCI electrocardiogramsMyocardial infarction (TIMI) flowMyocardial Infarction trialEvaluation of XIENCE V Everolimus-Eluting and Taxus Express2 Paclitaxel-Eluting Coronary Stents in Patients With Jailed Side Branches From the SPIRIT IV Trial at 2 Years
Forrest JK, Lansky AJ, Meller SM, Hou L, Sood P, Applegate RJ, Wang JC, Skelding KA, Shah A, Kereiakes DJ, Sudhir K, Cristea E, Yaqub M, Stone GW. Evaluation of XIENCE V Everolimus-Eluting and Taxus Express2 Paclitaxel-Eluting Coronary Stents in Patients With Jailed Side Branches From the SPIRIT IV Trial at 2 Years. The American Journal Of Cardiology 2013, 111: 1580-1586. PMID: 23499270, DOI: 10.1016/j.amjcard.2013.01.330.Peer-Reviewed Original ResearchConceptsSPIRIT IV trialMajor adverse cardiac eventsAdverse cardiac eventsClinical outcomesXIENCE VTarget lesionsCardiac eventsNovo native coronary artery lesionsIschemia-driven target vessel revascularizationTwo-year clinical outcomesNative coronary artery lesionsSPIRIT IIISide branchesXIENCE V EverolimusTarget lesion failureTarget vessel revascularizationCoronary artery lesionsPercutaneous coronary interventionSuperior clinical outcomesTreatment of patientsCoronary stent systemDrug-eluting stentsDiverse patient populationsEverolimus-ElutingSPIRIT IV
2012
Safety and Efficacy of High- Versus Low-Dose Aspirin After Primary Percutaneous Coronary Intervention in ST-Segment Elevation Myocardial Infarction The HORIZONS-AMI (Harmonizing Outcomes With Revascularization and Stents in Acute Myocardial Infarction) Trial
Yu J, Mehran R, Dangas GD, Claessen BE, Baber U, Xu K, Parise H, Fahy M, Lansky AJ, Witzenbichler B, Grines CL, Guagliumi G, Kornowski R, Wöhrle J, Dudek D, Weisz G, Stone GW. Safety and Efficacy of High- Versus Low-Dose Aspirin After Primary Percutaneous Coronary Intervention in ST-Segment Elevation Myocardial Infarction The HORIZONS-AMI (Harmonizing Outcomes With Revascularization and Stents in Acute Myocardial Infarction) Trial. JACC Cardiovascular Interventions 2012, 5: 1231-1238. PMID: 23257371, DOI: 10.1016/j.jcin.2012.07.016.Peer-Reviewed Original ResearchConceptsPrimary percutaneous coronary interventionST-segment elevation myocardial infarctionLow-dose aspirinElevation myocardial infarctionHigh-dose aspirinPrimary PCIHORIZONS-AMI trialPercutaneous coronary interventionMyocardial infarctionMajor bleedingCoronary interventionIschemic target vessel revascularizationMajor adverse cardiovascular eventsCoronary artery bypass surgeryLong-term patient outcomesAdverse ischemic eventsAdverse cardiovascular eventsDose of aspirinTarget vessel revascularizationArtery bypass surgeryHistory of hypertensionPremature coronary diseaseLong-term outcomesIschemic benefitAspirin doseFirst report of a novel abluminal groove filled biodegradable polymer rapamycin-eluting stent in de novo coronary artery disease: results of the first in man FIREHAWK trial.
Qian J, Xu B, Lansky AJ, Yang YJ, Qiao SB, Wu YJ, Chen J, Hu FH, Yang WX, Mintz GS, Leon MB, Gao RL. First report of a novel abluminal groove filled biodegradable polymer rapamycin-eluting stent in de novo coronary artery disease: results of the first in man FIREHAWK trial. Chinese Medical Journal 2012, 125: 970-6. PMID: 22613516.Peer-Reviewed Original ResearchConceptsMajor adverse cardiac eventsQuantitative coronary angiographyDrug-eluting stentsAbluminal grooveMyocardial infarctionDe novo coronary artery diseaseDe novo native coronary stenosisIschemia-driven target lesion revascularizationNovo coronary artery diseaseStent late lumen lossFirst-generation drug-eluting stentsComplete strut coverageAdverse cardiac eventsTarget lesion revascularizationTarget vessel revascularizationClinical success rateCoronary artery diseaseLate lumen lossNative coronary stenosisPrior myocardial infarctionStent late lossLate DES thrombosisLong-term restenosisLesion revascularizationPrimary endpointComparison of clinical and angiographic prognostic risk scores in patients with acute coronary syndromes: Analysis from the Acute Catheterization and Urgent Intervention Triage StrategY (ACUITY) trial
Palmerini T, Caixeta A, Genereux P, Cristea E, Lansky A, Mehran R, Dangas G, Lazar D, Sanchez R, Fahy M, Xu K, Stone GW. Comparison of clinical and angiographic prognostic risk scores in patients with acute coronary syndromes: Analysis from the Acute Catheterization and Urgent Intervention Triage StrategY (ACUITY) trial. American Heart Journal 2012, 163: 383-391.e5. PMID: 22424008, DOI: 10.1016/j.ahj.2011.11.010.Peer-Reviewed Original ResearchConceptsPercutaneous coronary interventionCardiac Surgery (SYNTAX) scoreNet reclassification improvementAcute coronary syndromePrognostic risk scoreMyocardial infarctionRisk scoreAngiographic variablesVessel revascularizationCardiac mortalityCoronary syndromeEnd pointSurgery scoreSegment elevation acute coronary syndromesUrgent Intervention Triage Strategy (ACUITY) trialAcute Coronary Events (GRACE) scoreElevation acute coronary syndromeNew risk stratification scoreEjection fraction (ACEF) scoreIschemic end pointsMyocardial Infarction (TIMI) scoreTarget vessel revascularizationRisk stratification scoresCoronary artery diseaseMost end points
2011
Long-Term Impact of Chronic Kidney Disease in Patients With ST-Segment Elevation Myocardial Infarction Treated With Primary Percutaneous Coronary Intervention The HORIZONS-AMI (Harmonizing Outcomes With Revascularization and Stents in Acute Myocardial Infarction) Trial
Saltzman AJ, Stone GW, Claessen BE, Narula A, Leon-Reyes S, Weisz G, Brodie B, Witzenbichler B, Guagliumi G, Kornowski R, Dudek D, Metzger DC, Lansky AJ, Nikolsky E, Dangas GD, Mehran R. Long-Term Impact of Chronic Kidney Disease in Patients With ST-Segment Elevation Myocardial Infarction Treated With Primary Percutaneous Coronary Intervention The HORIZONS-AMI (Harmonizing Outcomes With Revascularization and Stents in Acute Myocardial Infarction) Trial. JACC Cardiovascular Interventions 2011, 4: 1011-1019. PMID: 21939942, DOI: 10.1016/j.jcin.2011.06.012.Peer-Reviewed Original ResearchMeSH KeywordsAgedAged, 80 and overAngioplasty, Balloon, CoronaryAnticoagulantsChi-Square DistributionChronic DiseaseDrug-Eluting StentsEuropeFemaleFibrinolytic AgentsHemorrhageHeparinHirudinsHumansIsraelKaplan-Meier EstimateKidney DiseasesMaleMetalsMiddle AgedMyocardial InfarctionPeptide FragmentsPlatelet Aggregation InhibitorsPlatelet Glycoprotein GPIIb-IIIa ComplexProportional Hazards ModelsProspective StudiesProsthesis DesignRecombinant ProteinsRecurrenceRisk AssessmentRisk FactorsStentsStrokeThrombosisTime FactorsTreatment OutcomeUnited StatesConceptsST-segment elevation myocardial infarctionGlycoprotein IIb/IIIa inhibitorsPrimary percutaneous coronary interventionNet adverse cardiac eventsChronic kidney diseasePercutaneous coronary interventionTarget vessel revascularizationBare metal stentsDrug-eluting stentsHORIZONS-AMI trialElevation myocardial infarctionMajor bleedingBivalirudin monotherapyCoronary interventionKidney diseaseMyocardial infarctionRate of TVRIschemia-driven target vessel revascularizationNon-coronary artery bypassIIb/IIIa inhibitorsBenefit of bivalirudinDifferent antithrombotic strategiesAdverse cardiac eventsComposite of deathHigh ratePrognostic Impact of Staged Versus “One-Time” Multivessel Percutaneous Intervention in Acute Myocardial Infarction Analysis From the HORIZONS-AMI (Harmonizing Outcomes With Revascularization and Stents in Acute Myocardial Infarction) Trial
Kornowski R, Mehran R, Dangas G, Nikolsky E, Assali A, Claessen BE, Gersh BJ, Wong SC, Witzenbichler B, Guagliumi G, Dudek D, Fahy M, Lansky AJ, Stone GW, Investigators H. Prognostic Impact of Staged Versus “One-Time” Multivessel Percutaneous Intervention in Acute Myocardial Infarction Analysis From the HORIZONS-AMI (Harmonizing Outcomes With Revascularization and Stents in Acute Myocardial Infarction) Trial. Journal Of The American College Of Cardiology 2011, 58: 704-711. PMID: 21816305, DOI: 10.1016/j.jacc.2011.02.071.Peer-Reviewed Original ResearchConceptsPrimary percutaneous coronary interventionST-segment elevation myocardial infarctionMultivessel primary percutaneous coronary interventionMajor adverse cardiovascular eventsHORIZONS-AMI trialAdverse cardiovascular eventsMultivessel diseaseNonculprit lesionsCardiovascular eventsStent thrombosisPCI strategyPrimary PCIAcute Myocardial Infarction AnalysisProbable stent thrombosisTarget vessel revascularizationElevation myocardial infarctionPercutaneous coronary interventionSubgroup of patientsPrimary PCI proceduresMultivessel percutaneous interventionNonculprit vesselsCardiac mortalityCause mortalityCulprit lesionSTEMI patients
2010
The relative effects of abciximab and tirofiban on platelet inhibition and C-reactive protein during coronary intervention.
Saltzman AJ, Mehran R, Hooper WC, Moses JW, Weisz G, Collins MB, Lansky AJ, Kreps EM, Leon MB, Stone GW, Dangas G. The relative effects of abciximab and tirofiban on platelet inhibition and C-reactive protein during coronary intervention. Journal Of Invasive Cardiology 2010, 22: 2-6. PMID: 20048389.Peer-Reviewed Original ResearchMeSH KeywordsAbciximabAgedAngina, UnstableAngioplasty, Balloon, CoronaryAntibodies, MonoclonalBlood PlateletsC-Reactive ProteinDose-Response Relationship, DrugDouble-Blind MethodDrug Therapy, CombinationFemaleHeparinHumansImmunoglobulin Fab FragmentsMaleMiddle AgedPilot ProjectsPlatelet AggregationPlatelet Aggregation InhibitorsStentsTime FactorsTirofibanTyrosineConceptsPercutaneous coronary interventionC-reactive proteinTarget vessel revascularizationPlatelet inhibitionCoronary interventionLevels of CRPInflammatory markers C-reactive proteinPlatelet aggregationC-reactive protein levelsDouble-blind study designEfficacy of tirofibanLower platelet inhibitionCoronary artery bypassCoronary artery revascularizationArtery revascularizationDiabetic subsetEligible patientsNonfatal MIArtery bypassHs-CRPVessel revascularizationSpearman correlation coefficient modelClinical endpointsFirst time pointTirofiban
2009
5-Year Clinical Outcomes After Sirolimus-Eluting Stent Implantation Insights From a Patient-Level Pooled Analysis of 4 Randomized Trials Comparing Sirolimus-Eluting Stents With Bare-Metal Stents
Caixeta A, Leon MB, Lansky AJ, Nikolsky E, Aoki J, Moses JW, Schofer J, Morice MC, Schampaert E, Kirtane AJ, Popma JJ, Parise H, Fahy M, Mehran R. 5-Year Clinical Outcomes After Sirolimus-Eluting Stent Implantation Insights From a Patient-Level Pooled Analysis of 4 Randomized Trials Comparing Sirolimus-Eluting Stents With Bare-Metal Stents. Journal Of The American College Of Cardiology 2009, 54: 894-902. PMID: 19712798, DOI: 10.1016/j.jacc.2009.04.077.Peer-Reviewed Original ResearchConceptsBare metal stentsTarget vessel revascularizationStent thrombosisRate of deathMyocardial infarctionVessel revascularizationPooled analysisAcademic Research Consortium definitionsPatient-level pooled analysisDrug-eluting stent implantationArterial healing responseComposite of deathProbable stent thrombosisLong-term safetyDrug-eluting stentsLate stent thrombosisClinical outcomesRandomized trialsStent implantationSuperior efficacyBMS groupThrombosisHealing responseSES groupStentsImpact of Thienopyridine Administration Prior to Primary Stenting in Acute Myocardial Infarction
RABBANI LE, IYENGAR S, DANGAS GD, GRINES CL, COX DA, GARCIA E, TCHENG JE, GRIFFIN JJ, GUAGLIUMI G, STUCKEY T, TURCO M, STANT J, FAHY M, LANSKY AJ, MEHRAN R, STONE GW. Impact of Thienopyridine Administration Prior to Primary Stenting in Acute Myocardial Infarction. Journal Of Interventional Cardiology 2009, 22: 378-384. PMID: 19496901, DOI: 10.1111/j.1540-8183.2009.00474.x.Peer-Reviewed Original ResearchMeSH KeywordsAbciximabAgedAngioplasty, Balloon, CoronaryAntibodies, MonoclonalAspirinConfidence IntervalsDrug Therapy, CombinationDrug-Eluting StentsFemaleHumansImmunoglobulin Fab FragmentsKaplan-Meier EstimateMaleMiddle AgedMultivariate AnalysisMyocardial InfarctionMyocardial RevascularizationOdds RatioPlatelet Aggregation InhibitorsPreoperative CarePyridinesTime FactorsConceptsMajor adverse cardiovascular eventsAcute myocardial infarctionTarget vessel revascularizationIschemic target vessel revascularizationPrimary stentingThienopyridine administrationLoading doseTH patientsStent implantationMyocardial infarctionClopidogrel loading doseAdverse cardiovascular eventsSuperior clinical outcomesBare-metal stentingAbciximab useCADILLAC trialCardiovascular eventsVessel revascularizationClinical outcomesMetal stentingProcedural characteristicsOperator's discretionPatientsStentingCore labSafety and Efficacy of Drug-Eluting and Bare Metal Stents
Kirtane AJ, Gupta A, Iyengar S, Moses JW, Leon MB, Applegate R, Brodie B, Hannan E, Harjai K, Jensen LO, Park SJ, Perry R, Racz M, Saia F, Tu JV, Waksman R, Lansky AJ, Mehran R, Stone GW. Safety and Efficacy of Drug-Eluting and Bare Metal Stents. Circulation 2009, 119: 3198-3206. PMID: 19528338, DOI: 10.1161/circulationaha.108.826479.Peer-Reviewed Original ResearchConceptsBare metal stentsDrug-eluting stentsTarget vessel revascularizationMyocardial infarctionVessel revascularizationObservational studyMetal stentsEfficacy end pointTotal patientsOverall mortalityDrug-ElutingDES useLabel indicationsLabel useResidual confoundingBMS useRCTsPatientsDrug AdministrationInfarctionRevascularizationEnd pointMortality dataComparable reductionStentsPaclitaxel-Eluting Stents versus Bare-Metal Stents in Acute Myocardial Infarction
Stone GW, Lansky AJ, Pocock SJ, Gersh BJ, Dangas G, Wong SC, Witzenbichler B, Guagliumi G, Peruga JZ, Brodie BR, Dudek D, Möckel M, Ochala A, Kellock A, Parise H, Mehran R. Paclitaxel-Eluting Stents versus Bare-Metal Stents in Acute Myocardial Infarction. New England Journal Of Medicine 2009, 360: 1946-1959. PMID: 19420364, DOI: 10.1056/nejmoa0810116.Peer-Reviewed Original ResearchMeSH KeywordsAdultAgedAged, 80 and overAngioplasty, Balloon, CoronaryCombined Modality TherapyCoronary AngiographyCoronary RestenosisCoronary StenosisDrug-Eluting StentsFemaleFibrinolytic AgentsFollow-Up StudiesHumansKaplan-Meier EstimateMaleMiddle AgedMyocardial InfarctionPaclitaxelRecurrenceRetreatmentRiskStentsSwedenConceptsST-segment elevation myocardial infarctionPrimary percutaneous coronary interventionPaclitaxel-eluting stentsBare metal stentsElevation myocardial infarctionTarget lesion revascularizationMyocardial infarctionAngiographic evidenceEnd pointStent thrombosisIschemia-driven target lesion revascularizationPrimary PCIComposite safety end pointIdentical bare-metal stentMajor secondary end pointPrimary end pointSafety end pointSecondary end pointsTarget vessel revascularizationPercutaneous coronary interventionRepeat revascularization proceduresAcute myocardial infarctionSafety outcome measuresDrug-eluting stentsBinary restenosisImpact of Myocardial Bridge on Clinical Outcome After Coronary Stent Placement
Tsujita K, Maehara A, Mintz GS, Doi H, Kubo T, Castellanos C, Liu J, Yang J, Oviedo C, Franklin-Bond T, Sugirtharaj DD, Dangas GD, Lansky AJ, Stone GW, Moses JW, Leon MB, Mehran R. Impact of Myocardial Bridge on Clinical Outcome After Coronary Stent Placement. The American Journal Of Cardiology 2009, 103: 1344-1348. PMID: 19427426, DOI: 10.1016/j.amjcard.2009.01.340.Peer-Reviewed Original ResearchConceptsTarget lesion revascularizationCoronary stent placementStent placementMyocardial bridgeArtery lesionsObstructive lesionsClinical outcomesStent groupTarget lesion revascularization rateStent group patientsTarget vessel revascularizationComposite end pointCoronary artery lesionsMinimum stent areaGroup patientsRevascularization ratesConsecutive patientsLeft anteriorObstructive diseaseSystolic compressionCoronary arterySignificant plaqueStent areaStent restenosisIntravascular ultrasound